Project Grant R01AI186632
Award Date
9/12/24
Completion Date
7/31/29
Dollars Obligated
$646K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Providence, RI 02906, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,314,701.00 to support research focused on optimizing dolutegravir-based antiretroviral therapy (ART) in children and adolescents. The primary award recipient is the University of Florida, which will oversee the overall research project. The project includes sub-awards to Kwame Nkrumah University of Science...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,912 to the University of Ghana Medical Centre to conduct research on the pharmacokinetics and pharmacogenomics of dolutegravir-based antiretroviral therapy in young people living with HIV in Ghana. The key objectives of this research project are to: 1) Determine rates of dolutegravir-based antiretroviral therapy...
This federal Project Grant award of $756,077, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports a 5-year research study on the long-term immunologic, cardiovascular, metabolic, and neurocognitive consequences of inflammation in children with perinatal HIV in sub-Saharan Africa. The primary objectives are to assess the durability of inflammation and immune...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $820,845 to New York University School of Medicine to conduct research aimed at improving HIV outcomes across diverse settings and subgroups in the U.S. HIV epidemic. The research will use mathematical modeling to simulate alternative ways to distribute resources across interventions, settings, and target...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $108,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Kenyatta National Hospital (KNH) in Kenya. The purpose of this 2-year grant, with an award date of August 1, 2024 and a completion date of January 31, 2026, is to strengthen KNH's pre-award grants management capacity. The key products and services to be delivered through this funding include: 1) Training two senior research...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $884,322 to support research into the mechanisms that create and sustain the HIV reservoir - a population of latently infected cells that persists during suppressive antiretroviral therapy and prevents a cure for HIV. The research team, led by Dr. Reeves and collaborators at the Fred Hutchinson Cancer...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund a cluster randomized controlled trial to test the impact of a long-term, dynamic choice intervention on 12-month viral suppression among HIV clients experiencing treatment interruption in Malawi. The $653,677 award will be used to implement this research initiative over a project period from April 1, 2025 to January 31, 2030. The goal is to...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,547,482.00 to Trustees of Dartmouth College to conduct research aimed at improving the antiviral activity of broadly neutralizing antibodies (BNABs) against HIV. The research will focus on two strategies to enhance BNAB efficacy: Fc engineering to improve BNAB effector functions, and the use of BNAB combinations....
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to implement an innovative HIV self-testing and long-acting injectable HIV treatment and prevention intervention for commercial minibus drivers in Nigeria. The $809,692 award to The George Washington University, with sub-awards to Wake Forest University Health Sciences, University of Rochester, Emory...